SCHEMBL3484953

SCHEMBL3484953

CN(C1CCN(CC(=O)Nc2ccc(F)cc2)CC1)S(=O)(=O)c1ccccc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 4/20 0.61
APOBEC3A P31941 1/20 0.61
APOBEC3G Q9HC16 1/20 0.61
LMNA P02545 3/20 0.60
KDM4E B2RXH2 3/20 0.60
SMN1; SMN2 Q16637 2/20 0.56
CHRNB2 P17787 2/20 0.56
CHRNB4 P30926 2/20 0.56
CHRNA3 P32297 2/20 0.56
CHRNA4 P43681 2/20 0.56
ALDH1A1 P00352 2/20 0.56
KMT2A Q03164 2/20 0.55
MAPT P10636 1/20 0.55
HTT P42858 2/20 0.54
MEN1 O00255 1/20 0.54
PKM P14618 1/20 0.54
HTR2A P28223 2/20 0.53
HTR1A P08908 1/20 0.53
DRD2 P14416 1/20 0.53
HTR7 P34969 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3485444 0.88 LMNA (0.57) L3MBTL1LMNAKDM4ESMN1; SMN2CHRNB2
SCHEMBL3485838 0.88 TSHR (0.58) L3MBTL1APOBEC3AAPOBEC3GLMNAKDM4E
SCHEMBL3485749 0.85 LMNA (0.56) L3MBTL1LMNAKDM4ESMN1; SMN2ALDH1A1
SCHEMBL13541732 0.82 LMNA (0.52) L3MBTL1APOBEC3AAPOBEC3GLMNAKDM4E
SCHEMBL3485780 0.81 POLB (0.55) L3MBTL1LMNAKDM4ESMN1; SMN2ALDH1A1
SCHEMBL13541708 0.81 LTA4H (0.68) L3MBTL1LMNAKDM4ESMN1; SMN2CHRNB2
SCHEMBL3485542 0.80 SMN1; SMN2 (0.52) LMNAKDM4ESMN1; SMN2CHRNB2CHRNB4
SCHEMBL3485288 0.79 ALDH1A1 (0.53) LMNAKDM4ESMN1; SMN2CHRNB2CHRNB4
SCHEMBL3484955 0.79 CHRNB2 (0.58) L3MBTL1LMNAKDM4ESMN1; SMN2CHRNB2
SCHEMBL3485887 0.79 HTR2A (0.54) L3MBTL1LMNAKDM4EALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8791264-B2 Benzenesulfonamide compounds and their use as blockers of calcium channels PURDUE PHARMA L.P. (US) 2014-07-29 US claimed
US-20100022595-A1 Benzenesulfonamide Compounds and Their Use as Blockers of Calcium Channels PURDUE PHARMA L.P. (CT) 2010-01-28 US claimed
WO-2007118853-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS BLOCKERS OF CALCIUM CHANNELS EURO-CELTIQUE S.A. (LU) 2007-10-25 WO claimed
US-8791264-B2 Benzenesulfonamide compounds and their use as blockers of calcium channels PURDUE PHARMA L.P. (US) 2014-07-29 US disclosed
US-20100022595-A1 Benzenesulfonamide Compounds and Their Use as Blockers of Calcium Channels PURDUE PHARMA L.P. (CT) 2010-01-28 US disclosed
WO-2007118853-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS BLOCKERS OF CALCIUM CHANNELS EURO-CELTIQUE S.A. (LU) 2007-10-25 WO disclosed
WO-2007118853-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS BLOCKERS OF CALCIUM CHANNELS EURO-CELTIQUE S.A. (LU) 2007-10-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022595-A1 Benzenesulfonamide Compounds and Their Use as Blockers of Calcium Channels CACNA1A, CACNA1E, CACNA1B L3MBTL1 2644/4885APOBEC3A 4737/4885APOBEC3G 4758/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.